España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Verus International
VRUS
OTCEM
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
Get Report
Comment
Verus International (VRUS) Forecast
News
Earnings
Verus International (VRUS) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Verus International (OTC:VRUS) Stock
Verus International Stock (OTC: VRUS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, January 12, 2021
Verus International Completes A Requirments F...
Benzinga Newsdesk
Monday, December 28, 2020
Verus International Enters Into An Agreement ...
Benzinga Newsdesk
Tuesday, January 24, 2012
BioLineRx Surges after Hep C License Agreement
Benzinga
Thursday, January 19, 2012
Achillion's Hep C Pipeline Likely Can't Compete
Benzinga
Tuesday, January 17, 2012
Gilead Enters into $1.25B, 5 Year Credit Pact...
Benzinga
Pharmasset Hits 52-Week High of $136.99
Benzinga
Friday, January 13, 2012
Pharmasset Hits 52-Week High of $136.99
Benzinga
Thursday, January 12, 2012
Pharmasset Hits 52-Week High of $136.96
Benzinga
Wednesday, January 11, 2012
Pharmasset Hits 52-Week High of $136.40
Benzinga
Tuesday, January 10, 2012
Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target?
Benzinga
Monday, January 09, 2012
Forget Dendreon, Inhibitex is the New Biotech Success Story
Benzinga
Pharmasset Hits 52-Week High of $136.00
Benzinga
Friday, December 30, 2011
Pharmasset Spiking Higher
Benzinga
Tuesday, December 27, 2011
Best Biotech Stocks of 2011
Benzinga
Friday, December 16, 2011
Wedbush Securities Drops Coverage on Pharmass...
Benzinga
Robert W. Baird Downgrades Pharmasset to Neutral
Benzinga
Gilead Says it Remains Committed To Closing P...
Benzinga
JP Morgan Overweight on Gilead Sciences After Pharmasset QUANTUM Trial Announcement
Benzinga
Pharmasset Resumes Trading
Benzinga
PREVIEW: Pharmasset to Resume Trading at 8:20...
Benzinga
Pharmasset Announces Intent to Amend QUANTUM Trial
Benzinga
Pharmasset Halted, News Pending
Benzinga
Tuesday, December 06, 2011
Want More Tech ETFs? Global X Has Your Back
Benzinga
Pharmasset Spikes Lower on Heavy Volume
Benzinga
Monday, December 05, 2011
Citi Reiterates Buy, $49 PT on Gilead
Benzinga
J.P. Morgan Reiterates Overweight On Gilead
Benzinga
Thursday, December 01, 2011
Pharmasset Seeing Weak Tape, Will $11B Deal Go Through?
Benzinga
Tuesday, November 29, 2011
Brean Murray Raises Inhibitex PT to $19 From $12
Benzinga
Pharmasset Spiking Lower, May Be Attributed t...
Benzinga
Monday, November 28, 2011
Deutsche Bank Has Buy, $53 PT On Gilead
Benzinga
Investor Ideas' Biotech and Pharma Stock Investor Alert for Aethlon Medical, Vertex, Pharmasset
Benzinga
Credit Suisse Downgrades Pharmasset to Neutral
Benzinga
Friday, November 25, 2011
Investor Ideas' Hepatitis C Virus (HCV) Biotech and Pharma Stock Investor Alert
Benzinga
Tuesday, November 22, 2011
End-of-Day Market Summary for November 22, 2011
Benzinga
UPDATE: Canaccord Downgrades Pharmasset to Hold, Ups PT to $137 on Announced Deal
Benzinga
Brean Murray Downgrades Pharmasset to "Hold"
Benzinga
Brean Murray Downgrades Pharmasset to Hold, Removes PT
Benzinga
Wells Fargo Downgrades Pharmasset to Market Perform
Benzinga
Leerink Downgrades Pharmasset to Market Perform
Benzinga
A Peek Into The Market Before The Trading Starts
Benzinga
Piper Jaffray Reiterates Overweight Rating on Achillion Pharmaceuticals
Benzinga
Canaccord Downgrades Pharmasset to Hold
Benzinga
UBS Downgrades Pharmasset to Neutral
Benzinga
Benzinga's Top Downgrades
Benzinga
UPDATE: JP Morgan Downgrades Rating to Neutral, Raises PT to $137 on Pharmasset
Benzinga
Idenix and Spectrum Pharmaceuticals to Open Near 52-Week Highs
Benzinga
JP Morgan Downgrades Pharmasset to Neutral, Raises PT to $137
Benzinga
Monday, November 21, 2011
Pharmasset to Pay Gilead $331.9M Fee if Deal ...
Benzinga
Pharmasset Agreed Not to Solicit Talks on Oth...
Benzinga
Afternoon Movers; Healthcare Sector Up Significantly
Benzinga
Show More